ROTFL. You mean holders don't want to hear
facts. Their greed makes them think this one hit wonder
orphan drug for a very rare medical condition will miraculously turn CUV into the next CSL.
Afamelanotide aka Melanotan I is a synthetic version of the hormone alpha-MSH. It was developed as a
sunless tanning agent by the University of New Mexico in
1980. It has been out of patent for
>20 years. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.
An alternative synthesis method was patented by Chinese researchers in
2016.
Preparation method of melanotan I https://patents.google.com/patent/CN106243214B/en?q=melanotan&oq=melanotanThe
only patents CUV has relate to subcutaneous implants and topical ointments for a small number of medical conditions.These patents will begin to expire in
2023.
https://patents.google.com/?assignee=clinuvel&oq=clinuvelScenesse is an
Orphan Drug . This means it is
far easier to get get FDA approval.
The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (“drug”) to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphan status”). For a drug to qualify for orphan designation both the drug and the disease or condition must meet certain criteria specified in the ODA and FDA’s implementing regulations at 21 CFR Part 316.
https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-productsIf CUV had so much potential why would they CEO be selling?
(20min delay)